Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.

Article Details

Citation

Ramirez Rosas MB, Labruijere S, Villalon CM, Maassen Vandenbrink A

Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.

Expert Opin Pharmacother. 2013 Aug;14(12):1599-610. doi: 10.1517/14656566.2013.806487. Epub 2013 Jul 2.

PubMed ID
23815106 [ View in PubMed
]
Abstract

INTRODUCTION: The introduction of the triptans (5-hydroxytryptamine (5-HT)1B/1D receptor agonists) was a great improvement in the acute treatment of migraine. However, shortcomings of the triptans have prompted research on novel serotonergic targets for the treatment of migraine. AREAS COVERED: In this review the different types of antimigraine drugs acting at 5-HT receptors, their discovery and development are discussed. The first specific antimigraine drugs were the ergot alkaloids, consisting of ergotamine, dihydroergotamine and methysergide, which are agonists at 5-HT receptors, but can also bind alpha-adrenoceptors and dopamine receptors. In the 1990s, the triptans became available on the market. They are 5-HT1B/1D receptor agonists, showing fewer side effects due to their receptor specificity. In the last years, compounds that bind specifically to 5-HT1D, 5-HT1F and 5-HT7 receptors have been explored for their antimigraine potential. Furthermore, the serotonergic system seems to act in tight connection with the glutamatergic as well as the CGRP-ergic systems, which may open novel therapeutic avenues. EXPERT OPINION: Although the triptans are very effective in treating migraine attacks, their shortcomings have stimulated the search for novel drugs. Currently, the focus is on 5-HT1F receptor agonists, which seem devoid of vascular side effects. Moreover, novel compounds that affect multiple transmitter and/or neuropeptide systems that are involved in migraine could be of therapeutic relevance.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
Dihydroergotamine5-hydroxytryptamine receptor 1AProteinHumans
Unknown
Agonist
Details
Dihydroergotamine5-hydroxytryptamine receptor 1BProteinHumans
Yes
Agonist
Details
Dihydroergotamine5-hydroxytryptamine receptor 1DProteinHumans
Yes
Agonist
Details
Dihydroergotamine5-hydroxytryptamine receptor 1EProteinHumans
Unknown
Agonist
Details
Dihydroergotamine5-hydroxytryptamine receptor 1FProteinHumans
Yes
Agonist
Details
Dihydroergotamine5-hydroxytryptamine receptor 2AProteinHumans
Unknown
Agonist
Details
Dihydroergotamine5-hydroxytryptamine receptor 2BProteinHumans
Unknown
Agonist
Details
Dihydroergotamine5-hydroxytryptamine receptor 2CProteinHumans
Unknown
Agonist
Details
DihydroergotamineAlpha-1 adrenergic receptors (Protein Group)Protein groupHumans
Unknown
Agonist
Details
DihydroergotamineAlpha-2 adrenergic receptors (Protein Group)Protein groupHumans
Unknown
Agonist
Details
DihydroergotamineAlpha-2A adrenergic receptorProteinHumans
Unknown
Agonist
Details
DihydroergotamineDopamine D2 receptorProteinHumans
Unknown
Agonist
Details
DihydroergotamineDopamine D3 receptorProteinHumans
Unknown
Agonist
Details